Home > News > News Archive 2008

News Archive 2008

Page 1 of 4  > >>

17 Nov, 2008
Innocoll Receives Fast Track Designation for Gentamicin Surgical Implant
Category: 2008
Posted by: innocoll_admin
ASHBURN, Va., November 17, 2008 /PRNewswire/ -- -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the FDA has designated Gentamicin SURGICAL Implant as a Fast Track development program.  
[More]
25 Aug, 2008
Baxter announces Licensing Agreement for Innocoll’s Gentamicin Surgical Implant in the United States. The antibiotic surgical product may reduce incidence of surgical site infections and reduce post-operative cost and complications
Category: 2008
Posted by: innocoll_admin
DEERFIELD, Ill./ASHBURN, Va., August 25, 2008 — Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, a division of Innocoll, Inc., granting Baxter exclusive rights to market and distribute the company’s gentamicin surgical implant in the United States. The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections (SSIs) in the United States. This agreement is expected to add to Baxter’s biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post¬operative complications of SSIs during surgery.
[More]
08 Aug, 2008
Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Category: 2008
Posted by: innocoll_admin
ASHBURN, Va., August 8, 2008 /PRNewswire/ -- -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain.
[More]